Patients with recurrent genital herpes attending a sexually transmitted disease clinic were studied and transmission of the infection was elucidated by evaluating serostatus in their partners. Of 84 patients attending for recurrent genital herpes, 94% had a herpes simplex virus type 2 (HSV-2) infection and only 6% (5 patients) a type 1 infection. The mean age of the patients was 36 years and the duration of their infection was up to 37 years (median 4 years). In most patients the number of recurrences had not decreased between the ® rst year and the last year. About half had experienced a more severe ® rst episode infection. Of the patients, 64% were not aware of asymptomatic shedding and the risk of sexual transmission without clinical symptoms. Of 67 steady partners of patients with genital HSV-2, 15% had a history of genital herpes. By HSV serology, HSV-2 antibodies (indicating subclinical genital herpes) were demonstrated in more than half of the partners. The duration of the relationship or condom use did not seem to in¯uence the frequency of transmission to the partner, which may indicate an individual susceptibility for acquiring a genital HSV-2 infection. Eleven per cent of the patients were on suppressive antiviral therapy, while 39% had no experience of antiviral therapy. Type-speci® c HSV serology was found to be of value in counselling partners of patients with genital herpes. Key words: HSV types; serology; condom; subclinical infection; transmission. Gun-Britt Lo È whagen, Department of Dermatology and Venereology, Sahlgrenska University Hospital, SE-413 45, Go È teborg, Sweden. E-mail: gun-britt.lowhagen@sahlgrenska.se
Since type-speci® c serology for herpes simplex virus (HSV) types 1 and 2 was introduced, genital infection caused by HSV type 2 (HSV-2) has been shown to be one of the most common sexually transmitted diseases (STDs) in the Western world (1, 2) . An increasing number of cases of genital ® rstepisode herpes caused by HSV type 1 (HSV-1) has been reported, especially from Europe (3 ± 5) . The tendency to recur has been shown to be much lower for an HSV-1 than for an HSV-2 genital herpes infection (6) . Although a benign disease in most cases, genital herpes in many cases negatively in¯uences the patient's psychosexual and social life (7) . Much distress and concern relates to the risk of transmitting the virus to a partner. The aim of this study was to elucidate the spectrum of recurrent genital herpes in an STD population concerning the prevalence of HSV-1 and HSV-2 infections, number of recurrences and use of antiviral therapy, and to evaluate HSV-2 serology in partners without clinical disease.
PATIENTS AND METHODS

Patients
Consecutive patients with recurrent genital herpes, including new as well as long-term attendees, seen by the authors at the STD clinics of Sahlgrenska University Hospital and Bora Ê s Hospital between November 1996 and February 1999, were recruited to the study. In total, 84 patients, 49 men (age 18 ± 60, mean 36 years) and 35 women (age 21 ± 69, mean 36 years) were included.
Questionnaires
A structured questionnaire was ® lled in including questions about the duration of the disease, number of recurrences during the ® rst and last year, antiviral therapy, sexual history, including questions about the duration of the relationship, condom use and genital herpes in partners.
Partners
Patients with an HSV-2 infection who had a steady partner were asked to invite him or her to a visit at the clinic for counselling and a blood test for HSV-2 antibodies. Steady partner was de® ned as a partner in an ongoing relationship. Of 67 steady partners 26 (17 men, 9 women) agreed to attend the clinic. Information about the history of genital herpes in partners who did not attend was given by the index patients.
Virological methods
When blisters or erosions were present, specimens were collected for HSV culture and the isolated virus wastyped in a multiwell cell-culture system by means of an enzyme-linked immunosorbent assay (ELISA) and monoclonal antibodiesspeci® cally reacting with HSV-2 glycoprotein G (gG) and HSV-1 glycoprotein C (8). Blood was drawn for HSV serology and antibodiesreacting withtypecommonandtype 2 speci® c (gG)HSVantigen were assaye d by an ELISA-based method (9) .
Statistical methods
To test differences in the duration of relationship between seropositive and seronegative partners (seroconcordant and serodiscordant couples), the 95% con® dence interval (CI) for the difference between means of duration in the 2 groups was calculated.
The study was approved by the Ethics Committee of Go È teborg University and verbal informed consent was obtained from the patients.
HSV-1 infections
Of the 5 HSV-1 infections, 3 were veri® ed by culture and in 2 cases the diagnosis was based on the history, clinical picture and serology (positive for type common HSV antigen and negative for HSV-2). Of the 5 patients with HSV-1 infections, 3 were women and 2 men. Three patients had only 1 ± 2 recurrences per year, while 1 patient reported 4 and 1 patient 12 recurrences during the last year. Although 12 recurrences per year is uncommon for an HSV-1 infection the infection was not classi® ed as HSV-2 since the patient was seronegative for HSV-2. The HSV-1 infections are not included in the following presentation.
HSV-2 infections
Of 79 HSV-2 infections, 59 were veri® ed by positive culture and 20 by serology and a typical clinical picture.
Duration of the disease. Seventeen patients had a history of genital herpes of less than 1 year and 13 patients of more than 10 years (data were missing for 1 patient). Thirty-one (53%) of 59 recalled that their ® rst episode of genital herpes was much more severe than later episodes (see Table I ).
Recurrences. The number of recurrences during the ® rst and last year of infection are shown in Table I . Seventeen patients with a history of less than 1 year are not included, and when evaluating the number during the last year patients with a history of less than 2 years are not included. A further 14 patients could not give an estimate of the number of recurrences during the ® rst year of their infection and for the last year data were missing for 5 patients. For 37 patients with genital herpes for more than 2 years information concerning the number of recurrences was available from both their ® rst and last year with genital herpes. The number of recurrences had increased in 17 (46%) patients, decreased in 6 (16%) and was unchanged in 14 (38%).
Antiviral therapy. Twenty-seven of 70 patients had never taken antiviral therapy for their genital herpes, while 34 had experience of intermittent medication and 10 of suppressive therapy. Eight patients were on suppressive therapy at the time of the study.
Knowledge about transmission. Of 44 patients asked, 15 (34%) knew that the virus could be transmitted asymptomatically.
Partners. At the time of the study, 67 (85%) of 79 patients had an ongoing steady relationship (see Table II 
with a positive history were HSV-2 seropositive. Of 11 HSV-2 seronegative partners, all but 3 had antibodies against the type common HSV antigen. Two index patients were on suppressive antiviral therapy and in both cases their partners were seronegative. The duration of the relationship was for the seropositive partners (seroconcordants) median 3 years (2 months ± 20 years) and for the seronegative partners (serodiscordants) median 12 years (4 months ± 40 years). The difference between the means for duration of the relationship in the 2 groups was 85 months (95% CI ± 27 months to 197 months). A condom was used seldom or never by 8 of 11 (73%) and 11 of 15 (73%) subjects in the seronegative and seropositive group, respectively.
DISCUSSION
In 94% (79 of 84) of the patients attending the STD clinics for recurrent genital herpes, the infection was caused by HSV-2 and only in 6% (5 cases) by HSV-1. In a recurrent episode of genital herpes, virus replication is of short duration (1 ± 2 days) and the diagnosis was not veri® ed by culture in all cases. In 1983 Corey et al. (10) reported 5 cases (1%) caused by HSV-1 in a cohort of 362 patients with recurrent genital herpes. The proportion of HSV-1 infections in® rst episodes of genital herpes during the study period was as high as 50% (5). Although patients with genital herpes attending an STD clinic donot re¯ect the spectrum of the disease in the population, the low prevalence of HSV-1 infections indirectly supports the much better prognosis concerning recurrences compared with HSV-2. About half of the patients stated that they had a more severe ® rst episode of genital herpes. For some patients the ® rst episode of genital herpes does not re¯ecta recently acquired infection but the ® rst reactivation of a latent infection acquired asymptomatically, perhaps years previously (5, 11) . The median duration of genital herpes for 78 patients was 4 years, with a wide range from less than 1 year to 37 years. In 37 patients for whom information was available about the number of recurrences during the ® rst and last year, the number of recurrences had increased in 46%, decreased in 16% and was unchanged in 38%. This illustrates the variability among HSV-infected persons. The increasing number of recurrences from median 6 during the ® rst year to 8 during the last year when combining data from all patients probably re¯ects the fact that patients with increasing recurrences are more likely to attend. The number of recurrences was estimated by asking retrospectively and recall bias should be taken into consideration. In an observational cohort study by Benedetti et al. (12) , a signi® cant reduction in clinical disease occurred in the majority of patients. In most cases an HSV infection is acquired asymptomatically (13, 14) . Only 20 ± 30% of HSV-2-infected individuals have clinically recognized genital herpes (15 ± 17) . Asymptomatic shedding has been shown to occur with the same frequency among those with and without clinical disease (18) . In the present study, only 15% (10/67) of steady partners of patients with recurrent HSV-2 infection were aware of having genital herpes. By serology, HSV-2 antibodies could be demonstrated in 50% of partners without clinical genital herpes. The fact that partners had HSV-2 antibodies does not prove that their infections were acquired from their current partners. There was no positive correlation between the duration of the relationship and detectable HSV-2 infection in the partner. Neither was there any difference between discordant and concordant couples concerning condom use. This may indicate an individual susceptibility to contracting genital herpes. Bryson et al. (19) reported the results of 57 asymptomatic partners of index patients with recurrent HSV-2 genital herpes, 19% of whom were HSV-2 seropositive. The higher ® gure seen in the present study may re¯ect a higher background prevalence of HSV-2 infection and also the fact that duration of the relationships in these couples was longer: median 3 years for concordant couples and 12 years for discordant compared with 12.7 months and 23.6 months, respectively, in the couples studied by Bryson et al. In accordance with the present results, they did not ® nd any correlation between transmission and condom use, frequency of intercourse or the duration of relationship.
A challenge in counselling patients with genital herpes is to provide information about the risk of transmitting the virus between clinical recurrences. Of 44 patients asked, only 34% were aware of asymptomatic shedding. Continuous antiviral therapy decreases the asymptomatic shedding of the virus (20) but the impact of this therapy on transmission has not yet been proven. Although a group of patients with frequent recurrences was studied here, only 11% were on suppressive therapy and 39% had no experience of antiviral therapy. When judging the indication for antiviral therapy, the psychosexual and social effects of this disease on the patient must be taken into account. The type-speci® c serology could be of value in counselling couples.
